SU11248 (sunitinib malate) 2007
In two large international studies, Sutent was given as initial treatment for advance kidney
cancer and helped patients live longer.Previously, Sutent was approved to help people who fail
a first therapy. ...
Pfizer Inc. won US approval today to sell Sutent for fighting two hard-to-treat cancers of the
kidney and stomach. The FDA approved Sutent for treating GIST patients whose disease has
worsened after treatment with Novartis AG's Gleevec, or who cannot tolerate Gleevec.
Comparing to older generation of cancer drugs, Sutent is gentler on patients which may cause
less severe nausea and other harsh side effects. Sutent will cost about $37,713 per year.
---FDA approves Pfizer drug for two cancers, Reuters, January 26, 2006.